Benjamin Scott Savard is a writer, editor, and advocate for universal health care. He is working on a book about the challenges of insulin access in America.
Thanks to activist efforts, corporate and government policies have begun to make insulin more affordable for diabetics. These changes were won by exposing Big Pharma’s role in the US’s unjust for-profit health care system.
The three big insulin manufacturers recently announced some reductions in prices. But the price changes didn’t come from corporate beneficence — they came from public and government pressure. And they don’t go nearly far enough.